Frontlight ResearchEarly access
Ovarian cancer trials in Mexico
11 trials · From ClinicalTrials.gov, checked 16 November 2026. Ask the study team whether a trial fits you.
- No phaseNot yet taking people in MexicoMolecular Ovarian Cancer Assessment in LatiNoAmerican PAtients
- Where
- Mexico City, Nuevo León
- Age
- 18 years and over
- People
- 320 worldwide
- Run by
- Latin American Cooperative Oncology Group
See details and how to joinNCT07771400 - Phase 3Taking peopleA Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Where
- Aguascalientes, Cuauhtémoc, Guadalajara, Mexico City, Monterrey, Oaxaca City
- Age
- 18 years and over
- People
- 770 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06824467 · EU 2023-508015-23-00 - Phase 3Taking peopleEvaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Where
- Mexico City
- Age
- 18 years to 60 years
- People
- 3,960 worldwide
- Run by
- NRG Oncology
See details and how to joinNCT05879926 - Phase 3Taking peopleA Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Where
- Chihuahua City, Mexico City, Puebla City, Tijuana
- Age
- 18 years and over
- People
- 1,630 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07213804 · EU 2025-522255-25-00 - Phase 1/2Active, not recruitingA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Mérida, México
- Age
- 18 years and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00 - Phase 3Enrolling by invitationSafety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
- Where
- Guadalajara, Madero, Mexico City, San Juan del Río, Veracruz
- Age
- 18 years to 51 years
- People
- 250 worldwide
- Run by
- Tolmar Inc.
See details and how to joinNCT05645536 - Phase 3Taking peopleMinimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
- Where
- Tlalpan
- Age
- 18 years and over
- People
- 580 worldwide
- Run by
- M.D. Anderson Cancer Center
See details and how to joinNCT04575935 - No phaseTaking peopleStudy to Assess Prevalence of the Folate Receptor Alpha (FRa) in Adult Female Participants With Ovarian Cancer in Intercontinental (InterCon) Countries
- Where
- Mexico City
- Age
- 18 years and over
- People
- 1,000 worldwide
- Run by
- AbbVie
See details and how to joinNCT07539844 - No phaseTaking peopleTUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
- Where
- Mexico City
- Age
- 25 years to 50 years
- People
- 3,000 worldwide
- Run by
- University Medical Center Nijmegen
See details and how to joinNCT04294927 - No phaseTaking peopleLaparoscopic Interval Cytoreductive Surgery in Advance Ovarian Cancer
- Where
- México
- Age
- 18 years to 80 years
- People
- 33
- Run by
- Instituto Nacional de Cancerologia de Mexico
See details and how to joinNCT06883409 - Phase 2Taking peopleHIPEC in Ovarian Carcinoma Clinical Stage IIIC and IV During Interval Laparotomy
- Where
- Mexico City
- Age
- 18 years to 70 years
- People
- 100
- Run by
- Instituto Nacional de Cancerologia de Mexico
See details and how to joinNCT03275194